Skip to main content Back to Top
Advertisement

8/3/2020

Leucovorin Calcium Injection

Products Affected - Description

    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 50 mL vial, 1 count, NDC 63323-0631-50
    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0711-00
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 50 mg, vial, 1 count, NDC 00143-9555-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Hikma, 350 mg, vial, 1 count, NDC 00143-9552-01
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 100 mg, vial, 10 count, NDC 25021-0814-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 200 mg, vial, 1 count, NDC 25021-0815-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 350 mg, vial, 1 count, NDC 25021-0816-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 500 mg, vial, 1 count, NDC 25021-0828-50
    • Leucovorin Calcium lyophilized powder for solution for injection, Sagent, 50 mg, vial, 10 count, NDC 25021-0813-10

Reason for the Shortage

    • Fresenius Kabi has leucovorin on shortage due to manufacturing delays and increased demand.
    • Hikma did not provide a reason for the current shortage.
    • Mylan did not provide a reason for the current shortage.
    • Sagent has leucovorin on shortage due to manufacturing delays.
    • Teva has leucovorin available.

Available Products

    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 1 count, NDC 63323-0631-10
    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 200 mg, vial, 1 count, NDC 63323-0710-50
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 100 mg, vial, 1 count, NDC 00143-9554-01
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 200 mg, vial, 1 count, NDC 00143-9553-01
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional, 200 mg, vial, 1 count, NDC 67457-0529-20
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional, 350 mg, vial, 1 count, NDC 67457-0530-35
    • Leucovorin Calcium lyophilized powder for injection, Mylan Institutional, 50 mg, vial, 1 count, NDC 67457-0528-10
    • Leucovorin Calcium lyophilized powder for solution for injection, Teva, 100 mg, vial, 1 count, NDC 00703-5140-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Teva, 350 mg, vial, 1 count, NDC 00703-5145-01

Estimated Resupply Dates

    • Fresenius Kabi has leucovorin 500 mg on back order and the company estimates a release date of early-August 2020. The 10 mg/mL 50 mL vials are on back order and the company estimates a release date of late-August 2020.
    • Hikma has leucovorin 50 mg vials and 350 mg vials on back order and the company estimates a release date of late-August to early-September 2020.
    • Sagent has leucovorin 50 mg, 100 mg, 200 mg, 350 mg, and 500 mg vials on back order and the company estimates a release date of December 2020.

Updated

Updated August 3, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 6, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.